Developer docs
API playgroundTry for free, no card

Search company profiles

Akero Therapeutics

Full company profile

uuid00009rs

Namestring
Akero Therapeutics
Legal namestring
Akero Therapeutics, Inc.
Websiteurl
akerotx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Akero Therapeutics is a clinical-stage biotechnology company founded in 2017 by Apple Tree Partners to develop efruxifermin (EFX), an investigational engineered Fc-FGF21 fusion protein designed to treat metabolic dysfunction-associated steatohepatitis (MASH). The molecule consists of two FGF21 analogues connected to an Fc domain, extending half-life and enabling sustained signaling through FGF21 receptors in liver and adipose tissue to address the metabolic, inflammatory, and fibrotic drivers of MASH. The company advanced EFX through Phase 2a (BALANCED), Phase 2b (HARMONY in F2/F3 patients and SYMMETRY in compensated cirrhosis F4), and three Phase 3 trials (SYNCHRONY Histology, SYNCHRONY Real-World, SYNCHRONY Outcomes) targeting the full MASH disease spectrum.

EFX received FDA Breakthrough Therapy Designation in 2022 based on HARMONY readout, which showed statistically significant fibrosis improvement at Week 24 and sustained benefit through Week 96. Manufacturing is supported through partnerships with Boehringer Ingelheim and Vetter Pharma, and the technology foundation is built on an exclusive FGF21 license from Amgen. The company raised over $1.1 billion in cumulative capital across Series A/B rounds, a 2019 NASDAQ IPO, and multiple follow-on public offerings through 2024.

Akero was acquired by Novo Nordisk in December 2025 for $4.7 billion in cash (up to $5.2 billion including contingent value rights tied to EFX regulatory approval), becoming a wholly owned Novo Nordisk subsidiary with its common stock delisted from NASDAQ. Prior to acquisition, Akero was pre-revenue with no commercialized products; future EFX commercialization revenue, if approved, flows through Novo Nordisk's established global metabolic-disease sales infrastructure.

Short descriptiontext

Akero Therapeutics is a clinical-stage biotechnology company developing efruxifermin (EFX), an Fc-FGF21 fusion protein for the treatment of MASH across fibrosis stages F1-F4. Founded in 2017, Akero was acquired by Novo Nordisk in December 2025 for $4.7 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
MASH therapeutics, metabolic disease drugs, Fc-FGF21 fusion protein, liver disease biopharmaceuticals, fibrosis drug development
Industry2 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
MASH Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Commercialization (Post-Acquisition)
TypeOne Time License
Description

Akero was a pre-revenue clinical-stage company. As a Novo Nordisk subsidiary post-December 2025 acquisition, any future revenue from EFX commercialization will flow through Novo Nordisk's commercial operations.

akerotx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Akero Therapeutics is a clinical-stage biopharmaceutical company developing efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The lead asset is being evaluated across three Phase 3 trials in the SYNCHRONY program (Histology, Real-World, and Outcomes) for patients with MASH and moderate to advanced fibrosis. The company was acquired by Novo Nordisk in December 2025 to commercialize EFX.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • In Phase 2b HARMONY trial: EFX showed statistically significant improvements in fibrosis and MASH after 24 weeks in people with MASH with moderate or advanced fibrosis (F2/F3).
+2 more records
Product overview1 text field

Akero Therapeutics is a clinical-stage biotechnology company developing efruxifermin (EFX), a novel FGF21 analogue engineered as an Fc-FGF21 fusion protein for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company's development pipeline is anchored by EFX, which is currently in Phase 3 clinical trials through the SYNCHRONY program. Akero was acquired by Novo Nordisk in December 2025 to advance EFX through regulatory approval.

Product and service3 records
1Efruxifermin (EFX)
CategoryMASH Therapeutics
2HARMONY Phase 2b Trial
CategoryClinical Development Program
Description

A Phase 2b clinical trial (HARMONY) of EFX in patients with MASH and F2/F3 fibrosis, which showed statistically significant improvements in liver fibrosis without worsening of NASH.

3SYNCHRONY Phase 3 Program
CategoryClinical Development Program
Description

A Phase 3 clinical program comprising three trials (SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes) evaluating EFX in MASH patients. SYNCHRONY Outcomes is the only Phase 3 MASH trial with a hepatic clinical outcome primary endpoint.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Novo Nordisk acquired Akero Therapeutics for $4.7 billion (up to $5.2 billion with contingent payments), adding EFX to Novo Nordisk's portfolio of treatments across the stages of MASH. Deal completed December 9, 2025.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Collaboration where Hepta used Akero's SYNCHRONY Phase 3 program patient data to validate their blood test for identifying treatment-eligible MASH patients. Data showed Hepta's blood test outperformed three guideline-recommended non-invasive tests.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-01-01
Description

Akero entered into a license agreement with Amgen for FGF21 technology, which became the foundation for developing efruxifermin (EFX). This licensing deal was critical to establishing Akero's core technology platform.

4Boehringer-Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Manufacturing partnership established for the production of efruxifermin. Boehringer-Ingelheim is a leading global pharmaceutical contract manufacturer.

akerotx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Manufacturing partnership established for the production of efruxifermin. Vetter Pharma is a global contract development and manufacturing organization.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in MASH — developed resmetirom (Rezdiffra), the first FDA-approved therapy for MASH. Competes with Akero's EFX for the same hepatology patient population and prescriber base.

TypeBroad incumbent
Description

Acquired Akero in December 2025 for $4.7B and is itself developing semaglutide for MASH. Novo Nordisk is now both parent and a competing program owner within the MASH therapeutic area.

3Bristol-Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with a metabolic disease franchise and biologics manufacturing scale. Overlaps with Akero as a major-pharma competitor and potential partner in hepatology.

TypeDirect peer
Description

France-based clinical-stage biotech developing lanifibranor, a pan-PPAR agonist for MASH. Competes directly with EFX in the late-stage MASH clinical pipeline.

TypeEmerging player
Description

Previously developed aldafermin (FGF19 analog) for MASH and other metabolic programs. Operates in the same FGF-axis hepatology space and represents an adjacent metabolic disease competitor.

TypeBroad incumbent
Description

Major metabolic-disease incumbent with tirzepatide and broader MASH-adjacent programs. Represents a large-pharma competitor and potential strategic acquirer/partner for novel MASH assets like EFX.

TypeEmerging player
Description

Clinical-stage biotech with TERN-501, an oral thyroid receptor beta agonist for MASH. Represents a smaller-scale but mechanistically overlapping MASH competitor.

TypeDirect peer
Description

Clinical-stage metabolic disease biotech with VK2809 (thyroid receptor agonist) for MASH plus a broader metabolic pipeline. Competes with Akero for MASH prescriber mindshare and investor capital.

TypeBroad incumbent
Description

Pioneer in MASH drug development with obeticholic acid (OCALIVA). Despite regulatory setbacks in MASH, Intercept shaped the MASH development paradigm and overlaps with Akero in hepatology commercial strategy.

TypeDirect peer
Description

Closest mechanistic peer — developing pegozafermin, an FGF21 analog also being studied for MASH. Competes head-to-head with EFX in the FGF21 class and represents Akero's most direct clinical competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Akero Therapeutics

MASH Therapeuticsakerotx.com

Akero Therapeutics is a clinical-stage biotechnology company developing efruxifermin (EFX), an Fc-FGF21 fusion protein for the treatment of MASH across fibrosis stages F1-F4. Founded in 2017, Akero was acquired by Novo Nordisk in December 2025 for $4.7 billion.

What Akero Therapeutics does

Akero Therapeutics is a clinical-stage biotechnology company founded in 2017 by Apple Tree Partners to develop efruxifermin (EFX), an investigational engineered Fc-FGF21 fusion protein designed to treat metabolic dysfunction-associated steatohepatitis (MASH). The molecule consists of two FGF21 analogues connected to an Fc domain, extending half-life and enabling sustained signaling through FGF21 receptors in liver and adipose tissue to address the metabolic, inflammatory, and fibrotic drivers of MASH. The company advanced EFX through Phase 2a (BALANCED), Phase 2b (HARMONY in F2/F3 patients and SYMMETRY in compensated cirrhosis F4), and three Phase 3 trials (SYNCHRONY Histology, SYNCHRONY Real-World, SYNCHRONY Outcomes) targeting the full MASH disease spectrum.

EFX received FDA Breakthrough Therapy Designation in 2022 based on HARMONY readout, which showed statistically significant fibrosis improvement at Week 24 and sustained benefit through Week 96. Manufacturing is supported through partnerships with Boehringer Ingelheim and Vetter Pharma, and the technology foundation is built on an exclusive FGF21 license from Amgen. The company raised over $1.1 billion in cumulative capital across Series A/B rounds, a 2019 NASDAQ IPO, and multiple follow-on public offerings through 2024.

Akero was acquired by Novo Nordisk in December 2025 for $4.7 billion in cash (up to $5.2 billion including contingent value rights tied to EFX regulatory approval), becoming a wholly owned Novo Nordisk subsidiary with its common stock delisted from NASDAQ. Prior to acquisition, Akero was pre-revenue with no commercialized products; future EFX commercialization revenue, if approved, flows through Novo Nordisk's established global metabolic-disease sales infrastructure.

Akero Therapeutics firmographics

Firmographics
Name
Akero Therapeutics
Legal name
Akero Therapeutics, Inc.
Website
https://akerotx.com
Company type
Public
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Akero Therapeutics is a clinical-stage biotechnology company developing efruxifermin (EFX), an Fc-FGF21 fusion protein for the treatment of MASH across fibrosis stages F1-F4. Founded in 2017, Akero was acquired by Novo Nordisk in December 2025 for $4.7 billion.
Ownership category
akta.pro rank

Akero Therapeutics industry classification

Industry
Product category
MASH Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • MASH therapeutics
  • Metabolic disease drugs
  • Fc-FGF21 fusion protein
  • Liver disease biopharmaceuticals
  • Fibrosis drug development

Where Akero Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Akero Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Drug Commercialization (Post-Acquisition): Akero was a pre-revenue clinical-stage company. As a Novo Nordisk subsidiary post-December 2025 acquisition, any future revenue from EFX commercialization will flow through Novo Nordisk's commercial operations.

Go-to-market motion1 record

Marketing channels3 records

Akero Therapeutics product offering

Product offering

Core offering

Akero Therapeutics is a clinical-stage biopharmaceutical company developing efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The lead asset is being evaluated across three Phase 3 trials in the SYNCHRONY program (Histology, Real-World, and Outcomes) for patients with MASH and moderate to advanced fibrosis. The company was acquired by Novo Nordisk in December 2025 to commercialize EFX.

Product overview

Akero Therapeutics is a clinical-stage biotechnology company developing efruxifermin (EFX), a novel FGF21 analogue engineered as an Fc-FGF21 fusion protein for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company's development pipeline is anchored by EFX, which is currently in Phase 3 clinical trials through the SYNCHRONY program. Akero was acquired by Novo Nordisk in December 2025 to advance EFX through regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Efruxifermin (EFX)
  • HARMONY Phase 2b Trial A Phase 2b clinical trial (HARMONY) of EFX in patients with MASH and F2/F3 fibrosis, which showed statistically significant improvements in liver fibrosis without worsening of NASH.
  • SYNCHRONY Phase 3 Program A Phase 3 clinical program comprising three trials (SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes) evaluating EFX in MASH patients. SYNCHRONY Outcomes is the only Phase 3 MASH trial with a hepatic clinical outcome primary endpoint.

Quantifiable outcome

  • In Phase 2b HARMONY trial: EFX showed statistically significant improvements in fibrosis and MASH after 24 weeks in people with MASH with moderate or advanced fibrosis (F2/F3).
  • +2 more outcomes

Companies that use Akero Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Akero Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Akero Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Novo NordiskcoreStrategic or Co-development Partner · 9 December 2025Novo Nordisk acquired Akero Therapeutics for $4.7 billion (up to $5.2 billion with contingent payments), adding EFX to Novo Nordisk's portfolio of treatments across the stages of MASH. Deal completed December 9, 2025.
  • HeptaminorStrategic or Co-development Partner · 1 November 2025Collaboration where Hepta used Akero's SYNCHRONY Phase 3 program patient data to validate their blood test for identifying treatment-eligible MASH patients. Data showed Hepta's blood test outperformed three guideline-recommended non-invasive tests.
  • AmgencoreTechnology or Integration · 1 January 2018Akero entered into a license agreement with Amgen for FGF21 technology, which became the foundation for developing efruxifermin (EFX). This licensing deal was critical to establishing Akero's core technology platform.
  • Boehringer-IngelheimcoreStrategic or Co-development Partner · 1 January 2018Manufacturing partnership established for the production of efruxifermin. Boehringer-Ingelheim is a leading global pharmaceutical contract manufacturer.
  • Vetter PharmacoreStrategic or Co-development Partner · 1 January 2018Manufacturing partnership established for the production of efruxifermin. Vetter Pharma is a global contract development and manufacturing organization.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Akero Therapeutics competitors and assessment

Company assessment

Direct peers

  • Madrigal Pharmaceuticals: Direct competitor in MASH — developed resmetirom (Rezdiffra), the first FDA-approved therapy for MASH. Competes with Akero's EFX for the same hepatology patient population and prescriber base.
  • Inventiva: France-based clinical-stage biotech developing lanifibranor, a pan-PPAR agonist for MASH. Competes directly with EFX in the late-stage MASH clinical pipeline.
  • Viking Therapeutics: Clinical-stage metabolic disease biotech with VK2809 (thyroid receptor agonist) for MASH plus a broader metabolic pipeline. Competes with Akero for MASH prescriber mindshare and investor capital.
  • 89bio: Closest mechanistic peer — developing pegozafermin, an FGF21 analog also being studied for MASH. Competes head-to-head with EFX in the FGF21 class and represents Akero's most direct clinical competitor.

Broad incumbents

  • Novo Nordisk: Acquired Akero in December 2025 for $4.7B and is itself developing semaglutide for MASH. Novo Nordisk is now both parent and a competing program owner within the MASH therapeutic area.
  • Bristol-Myers Squibb: Large pharmaceutical company with a metabolic disease franchise and biologics manufacturing scale. Overlaps with Akero as a major-pharma competitor and potential partner in hepatology.
  • Eli Lilly: Major metabolic-disease incumbent with tirzepatide and broader MASH-adjacent programs. Represents a large-pharma competitor and potential strategic acquirer/partner for novel MASH assets like EFX.
  • Intercept Pharmaceuticals: Pioneer in MASH drug development with obeticholic acid (OCALIVA). Despite regulatory setbacks in MASH, Intercept shaped the MASH development paradigm and overlaps with Akero in hepatology commercial strategy.

Emerging players

  • NGM Biopharmaceuticals: Previously developed aldafermin (FGF19 analog) for MASH and other metabolic programs. Operates in the same FGF-axis hepatology space and represents an adjacent metabolic disease competitor.
  • Terns Pharmaceuticals: Clinical-stage biotech with TERN-501, an oral thyroid receptor beta agonist for MASH. Represents a smaller-scale but mechanistically overlapping MASH competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Akero Therapeutics social profiles

Digital presence

Akero Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Akero Therapeutics leadership team

Management profile

Number of profiles

Profiles24 records

Akero Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Akero Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akero Therapeutics

What does Akero Therapeutics do?

Akero Therapeutics is a clinical-stage biopharmaceutical company developing efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The lead asset is being evaluated across three Phase 3 trials in the SYNCHRONY program (Histology, Real-World, and Outcomes) for patients with MASH and moderate to advanced fibrosis. The company was acquired by Novo Nordisk in December 2025 to commercialize EFX.

Is Akero Therapeutics a public or private company?

Akero Therapeutics is a public company. It is classified as corporate owned and is currently acquired.

When was Akero Therapeutics founded?

Akero Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Akero Therapeutics based?

Akero Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Akero Therapeutics make money?

One revenue line is on record: drug Commercialization (Post-Acquisition).

Who are Akero Therapeutics's main competitors?

Direct peers on record are Madrigal Pharmaceuticals, Inventiva, Viking Therapeutics and 89bio. Broad incumbents are Novo Nordisk, Bristol-Myers Squibb, Eli Lilly and Intercept Pharmaceuticals. Emerging players are NGM Biopharmaceuticals and Terns Pharmaceuticals.

Does Akero Therapeutics have an API?

No public API is recorded for Akero Therapeutics.

What industry is Akero Therapeutics in?

Akero Therapeutics's product category is MASH Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market ResearchThe global NASH treatment market is projected to grow from USD 8.75 billion in 2025 to USD 46.87 billion by 2032, a CAGR of 27.1%. Growth depends on fibrosis-confirmed patients, with Rezdiffra and Wegovy establishing approved pathways. Late-stage pipelines from Eli Lilly and others may add treatment options.STATAkero, Leqembi, Sydnexis, Dizal: Readout NewsletterAstraZeneca is paying $600 million upfront to acquire global rights for the lung cancer drug Zegfrovy (an EGFR inhibitor) from Chinese firm Dizal Pharmaceutical Co., with the drug approved in the U.S. and China for advanced non-small cell lung cancer patients with certain mutations. The former executive team of Akero Therapeutics (recently sold to Novo Nordisk for $5 billion) has partnered with investment firm Fairmount to launch Avere Therapeutics, a new publicly traded biotech focused on developing an oral IL-23 targeted drug for autoimmune conditions.Endpoints NewsFormer Akero team announces new I&I company, Avere, with China drugThe former executive team behind Akero Therapeutics has announced a new company, Avere Therapeutics, focused on immunology and inflammation (I&I), with a drug sourced from China. The announcement comes after Akero was acquired by Novo Nordisk for $4.7 billion. Andrew Cheng has been named CEO of the newly formed Avere Therapeutics.TechBullion5 HealthTech Startups Developing Hepatology SolutionsThis article profiles five healthtech startups developing solutions for liver disease, a condition affecting hundreds of millions globally that often goes undiagnosed until advanced stages. The companies profiled—Akero Therapeutics, Madrigal Pharmaceuticals, Alentis Therapeutics, Enyo Pharma, and Pandorum Technologies—each take distinct approaches including drug development for MASH and Hepatitis B, antibody therapies for fibrosis and liver cancer, and bioengineered liver tissue. Madrigal Pharmaceuticals achieved a landmark in 2024 when the FDA approved Rezdiffra as the first treatment for MASH with liver fibrosis, while collectively these companies have raised over $1.4 billion, signaling significant investor interest in the hepatology space.CapitalИзтичането на патенти ускори сделките във фармациятаPatent expirations and improved market conditions drove M&A activity in the pharmaceutical sector in 2025. Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion, Novartis bought Avidity Biosciences for $12 billion, and Pfizer outbid Metsera for $10 billion. The deals reflect a renewed wave of acquisitions following a period of uncertainty.STATAkeso and Summit’s ivonescimab extends survival in squamous cell lung cancerAkeso's ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment in a Chinese trial. The data, presented at ASCO and published in The Lancet, exceeded oncologists' expectations and could boost optimism for the drug developed by Summit Therapeutics.Business Wire BlogHepta's Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH PatientsHepta announced clinical data showing its blood test outperformed three guideline-recommended non-invasive tests (FIB-4, ELF, and FibroScan) in identifying MASH patients eligible for treatment, achieving an AUC of 0.83 on hold-out validation. The 528-patient multi-cohort study used biopsy-confirmed patient data from Duke University, University Medical Center Mainz, and Akero Therapeutics' SYNCHRONY Phase 3 program. Results will be presented at EASL 2026 Congress in Barcelona on May 30, with the findings selected for oral presentation and recognized as Best of EASL 2026.The Motley FoolBest Healthcare Stocks to Buy in 2026Biogen and Novo Nordisk are compared as healthcare stocks, with Biogen awaiting FDA approval for a subcutaneous Leqembi formulation and Novo Nordisk seeing Wegovy sales rise after pill-form approval. Biogen's shares rose over 13.5% this year, while Novo Nordisk's fell nearly 8%, with Novo Nordisk favored as a better buy.BioSpaceBeyond Rezdiffra: The 4 Most Promising MASH Pipelines in PlayMadrigal Pharmaceuticals' Rezdiffra became the first approved MASH therapy in 2024 and has generated $817 million in revenue through Q3 2025, spurring three major Big Pharma acquisitions in the space totaling over $9.9 billion. GSK, Roche, and Novo Nordisk each acquired FGF21 analog developers in 2025, driven by Akero Therapeutics' positive efruxifermin mid-stage trial data in January 2025. Four differentiated late-stage pipeline candidates—Inventiva's lanifibranor, Viking Therapeutics' VK2809, Altimmune's pemvidutide, and Sagimet Biosciences' denifanstat—are now positioned as potential acquisition targets for 2026, with analysts predicting most smaller MASH biotechs will eventually be absorbed by Big Pharma.